

**S3 Table.** Scoring sheet according to New-Castle Ottawa scale

	Selection				Comparability	Outcome			Overall score (9 to be full)
	1	2	3	4	1	1	2	3	
	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure	Outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow- up long enough for outcomes to occur	Adequacy of follow-up of cohorts	
He, NSCLC [1]	1	1	1	1	0	1	1	1	7
Iyengar, NSCLC [2]	1	1	1	1	2	1	0	1	8
Sheu, NSCLC [3]	1	1	1	1	2	1	1	1	9
Yano, NSCLC [4]	1	1	1	1	0	1	1	1	7
Frost, NSCLC [5]	1	1	1	1	2	1	1	1	9
Gomez, NSCLC [6], [55]	1	1	1	1	2	1	1	1	9
Gray, NSCLC [7]	1	1	1	1	0	1	1	1	7
Hu, NSCLC [8]	1	1	1	1	0	1	1	1	7
Song, NSCLC [9]	1	1	1	1	2	1	1	1	9
Xu, NSCLC [10]	1	1	1	1	0	1	1	1	7
Ni, NSCLC [11]	1	1	1	1	0	1	1	1	7
Shang, NSCLC (postop) [12]	1	1	1	1	0	1	1	1	7
Gore, SCLC (extended) [13]	1	1	1	1	2	1	1	1	9
Xu, SCLC (extended) [14]	1	1	1	1	2	1	1	1	9
Bouman-Wammes, prostate [15]	1	1	1	1	0	1	1	1	7
Lan, prostate [16]	1	1	1	1	0	1	1	1	7
Ost, prostate [17]	1	1	1	1	2	1	1	1	9
Steuber, prostate [18]	1	1	1	1	2	1	1	1	9
Parker, prostate	1	1	1	1	2	1	1	1	9

[19]									
Tsumura, prostate [20]	1	1	1	1	0	1	1	1	7
Giessen, colorectal [21]	1	1	1	1	0	1	1	1	7
Ruer, colorectal [22]	1	1	1	1	2	1	1	1	9
Ruo, colorectal [23]	1	1	1	1	0	1	1	1	7
Chen, esophagus [24]	1	1	1	1	0	1	0	1	6
Depypere, esophagus [25]	1	1	1	1	0	1	1	1	7
Chen, HCC [26]	1	1	1	1	2	1	0	1	8
Pan, HCC [27]	1	1	1	1	2	1	1	1	9
Morino, bile duct [28]	1	1	1	1	2	1	1	1	9
Schulz, head and neck [29]	1	1	1	1	0	1	1	1	7
Falk, sarcoma [30]	1	1	1	1	0	1	1	1	7
Kagawa, NSCLC [31]	1	1	1	1	0	1	1	1	7
Hsu, KH, NSCLC [32]	1	1	1	1	0	1	1	1	7
Zhao Y, NSCLC [33]	1	1	1	1	0	1	1	1	7
Li H, NSCLC [34]	1	1	1	1	0	1	1	1	7
Gauvin, NSCLC [35]	1	1	1	1	0	1	1	1	7
Chen XR, NSCLC [36]	1	1	1	1	0	1	1	1	7
Wang, NSCLC [37]	1	1	1	1	0	1	0	1	6
Yildirim, prostate [39]	1	1	1	1	2	1	1	1	9

Phillips, prostate [40]	1	1	1	1	2	1	1	1	9
Deek, prostate [41]	1	1	1	1	0	1	1	1	7
Boeri, prostate [42]	1	1	1	1	0	1	1	1	7
Hu, multiple [43]	1	1	1	1	0	1	1	1	7
Palma, multiple [44]	1	1	1	1	2	1	1	1	9
Ji X, pancreas [45]	1	1	1	1	2	1	1	1	9
Shao Y, pancreas [46]	1	1	1	1	0	1	1	1	7
Lan, breast [47]	1	1	1	1	0	1	1	1	7
Moretto, colorectal [48]	1	1	1	1	0	1	1	1	7
Li J, esophagus [49]	1	1	1	1	0	1	1	1	7
Shi Z, esophagus [50]	1	1	1	1	2	1	1	1	9
Kim K, HCC [51]	1	1	1	1	2	1	1	1	9
Wang, HCC [38]	1	1	1	1	0	1	1	1	7
Li W, NPX. [52]	1	1	1	1	2	1	1	1	9
Wright, oropharynx [53]	1	1	1	1	0	1	1	1	7
Liu Y, RCC [54]	1	1	1	1	0	1	1	1	7

## References

1. He J, Li Y, An J, Hu L, Zhang J. Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis. *World J Surg Oncol.* 2017;15:36.
2. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. *JAMA Oncol.* 2018;4:e173501.
3. Sheu T, Heymach JV, Swisher SG, Rao G, Weinberg JS, Mehran R, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. *Int J Radiat Oncol Biol Phys.* 2014;90:850-7.

4. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. *J Surg Oncol*. 2010;102:852-5.
5. Frost N, Tessmer A, Schmittel A, van Laak V, Raspe M, Ruwwe-Glosenkamp C, et al. Local ablative treatment for synchronous single organ oligometastatic lung cancer: a propensity score analysis of 180 patients. *Lung Cancer*. 2018;125:164-73.
6. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. *J Clin Oncol*. 2019;37:1558-65.
7. Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. *Lung Cancer*. 2014;85:239-44.
8. Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, et al. Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. *Clin Lung Cancer*. 2019;20:e81-90.
9. Song YQ, Wang N, Qiao Y, He L, Li X, Zhang XF, et al. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis. *J Cancer Res Clin Oncol*. 2020;146:1021-31.
10. Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. *J Thorac Oncol*. 2018;13:1383-92.
11. Ni Y, Ye X, Yang X, Huang G, Li W, Wang J, et al. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment. *J Cancer Res Clin Oncol*. 2020;146:197-203.
12. Shang S, Wang L, Su Y, Li B, Guo M, Zhu Z, et al. Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer. *Future Oncol*. 2019;15:1593-603.
13. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. *J Thorac Oncol*. 2017;12:1561-70.
14. Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, et al. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. *Sci Rep*. 2017;7:9255.
15. Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, et al. Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET/CT. *Clin Genitourin Cancer*. 2017;15:e773-82.
16. Lan T, Chen Y, Su Q, Ye J. Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases. *Urology*. 2019;131:166-75.
17. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for

oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. *J Clin Oncol*. 2018;36:446-53.

18. Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. *Eur Urol Focus*. 2019;5:1007-13.
19. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *Lancet*. 2018;392:2353-66.
20. Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, et al. Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: a retrospective cohort study. *Prostate*. 2019;79:506-14.
21. Giessen C, Fischer von Weikersthal L, Laubender RP, Stintzing S, Modest DP, Schalhorn A, et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. *Br J Cancer*. 2013;109:1428-36.
22. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. *J Natl Cancer Inst*. 2017;109:djx015.
23. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. *J Am Coll Surg*. 2003;196:722-8.
24. Chen Y, Cheng X, Song H, Wu AJ, Ku GY, Lee P, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. *J Thorac Dis*. 2019;11:1536-45.
25. Depypere LP, Moons J, Lerut TE, Coosemans W, Van Veer H, Nafteux PR. Palliative esophagectomy in unexpected metastatic disease: sense or nonsense? *Asian Cardiovasc Thorac Ann*. 2018;26:552-7.
26. Chen J, Lu S, Zhang Y, Xu L, Chen J, Wang J, et al. Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases: a propensity score-matched analysis. *J Cancer*. 2018;9:1745-53.
27. Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis. *Radiology*. 2017;282:259-70.
28. Morino K, Seo S, Yoh T, Fukumitsu K, Ishii T, Taura K, et al. Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. *Ann Surg Oncol*. 2020;27:1908-17.
29. Schulz D, Wirth M, Piontek G, Knopf A, Straube C, Pigorsch S, et al. Improved overall survival in head and neck cancer patients after specific therapy of distant metastases. *Eur Arch Otorhinolaryngol*. 2018;275:1239-47.
30. Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. *Clin Oncol (R Coll Radiol)*. 2015;27:48-55.
31. Kagawa Y, Furuta H, Uemura T, Watanabe N, Shimizu J, Horio Y, et al. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. *Cancer Sci*. 2020;111:4442-52.
32. Hsu KH, Huang JW, Tseng JS, Chen KW, Weng YC, Yu SL, et al. Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment naive advanced EGFR-mutant lung adenocarcinoma patients. *Onco Targets Ther*. 2021;14:2139-48.

33. Zhao Y, Zhang X, Zhao H, Gong T, Li J, Tsao J, et al. Systemic therapy plus thermal ablation versus systemic therapy alone for oligometastatic liver metastases from non-small cell lung cancer. *Cardiovasc Intervent Radiol*. 2020;43:1285-93.
34. Li H, Duan Z, Zhao C, Fang W, Jia Y, Li X, et al. Combination of brachytherapy with iodine-125 seeds and systemic chemotherapy versus systemic chemotherapy alone for synchronous extracranial oligometastatic non-small cell lung cancer. *Cancer Manag Res*. 2020;12:8209-20.
35. Gauvin C, Krishnan V, Kaci I, Tran-Thanh D, Bedard K, Albadine R, et al. Survival impact of aggressive treatment and PD-L1 expression in oligometastatic NSCLC. *Curr Oncol*. 2021;28:593-605.
36. Chen XR, Hou X, Li DL, Sai K, Dinglin XX, Chen J, et al. Management of non-small-cell lung cancer patients initially diagnosed with 1 to 3 synchronous brain-only metastases: a retrospective study. *Clin Lung Cancer*. 2021;22:e25-34.
37. Wang P, Yin T, Zhao K, Yu J, Teng F. Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. *J Cancer Res Clin Oncol*. 2022;148:1253-61.
38. Wang H, Lu J, Zheng XT, Zha JH, Jing WD, Wang Y, et al. Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: computed tomography-guided (125)I seed implantation vs. second-line chemotherapy. *Front Oncol*. 2020;10:470.
39. Yildirim BA, Onal C, Kose F, Oymak E, Sedef AM, Besen AA, et al. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. *Strahlenther Onkol*. 2019;195:872-81.
40. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. *JAMA Oncol*. 2020;6:650-9.
41. Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C, et al. Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. *Eur Urol Oncol*. 2021;4:447-55.
42. Boeri L, Sharma V, Kwon E, Stish BJ, Davis BJ, Karnes RJ. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. *Prostate Cancer Prostatic Dis*. 2021;24:514-23.
43. Hu X, Li H, Kang X, Wang X, Pang H, Liu C, et al. Efficacy and safety of local radiotherapy to all oligometastatic sites in elderly patients with metachronous oligometastatic cancers after initial treatment for the primary tumor. *Cancer Manag Res*. 2021;13:9247-59.
44. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. *J Clin Oncol*. 2020;38:2830-8.
45. Ji X, Zhao Y, He C, Han S, Zhu X, Shen Z, et al. Clinical effects of stereotactic body radiation therapy targeting the primary tumor of liver-only oligometastatic pancreatic cancer. *Front Oncol*. 2021;11:659987.
46. Shao Y, Feng J, Hu Z, Wu J, Zhang M, Shen Y, et al. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma: a case-control study. *Ann Med Surg (Lond)*. 2021;62:490-4.
47. Lan B, Abudureheyimu N, Zhang J, Wang C, Jiang S, Wang J, et al. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. *Int J Cancer*. 2020;147:3199-205.
48. Moretto R, Rossini D, Zucchelli G, Lonardi S, Bergamo F, Santini D, et al. Oligometastatic colorectal cancer: prognosis, role of

locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. *Eur J Cancer*. 2020;139:81-9.

49. Li J, Wen Y, Xiang Z, Du H, Geng L, Yang X, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. *Radiother Oncol*. 2021;154:201-6.

50. Shi Z, Zhu X, Ke S, Qiu H, Cai G, Zhangcai Y, et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses. *Radiother Oncol*. 2021;164:236-44.

51. Kim K, Kim TH, Kim TH, Seong J. Efficacy of local rherapy for oligometastatic hepatocellular carcinoma: a propensity score matched analysis. *J Hepatocell Carcinoma*. 2021;8:35-44.

52. Li W, Bai Y, Wu M, Shen L, Shi F, Sun X, et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: propensity score matching analysis. *Oncotarget*. 2017;8:52132-41.

53. Wright CM, Lee DY, Shimunov D, Carmona R, Barsky AR, Sun L, et al. Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. *Oral Oncol*. 2021;121:105509.

54. Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S, et al. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. *World J Urol*. 2021;39:4183-90.

55. Gomez DR, Blumenschein GR, Jr., Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol*. 2016;17:1672-82.